Literature DB >> 12502497

Role for VPAC2 receptor-mediated signals in pancreas development.

Latif Rachdi1, Jean-Claude Marie, Raphael Scharfmann.   

Abstract

Mature pancreatic cells develop from progenitors that proliferate and differentiate into endocrine and exocrine cells. This development is thought to be controlled by secreted soluble factors acting on their target cells after binding to membrane receptors. Here, we analyzed the impact on embryonic pancreatic development of ligands that bind to protein G-coupled receptors and increase cAMP accumulation. We found that embryonic pancreatic epithelial cells were sensitive to vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide. These factors generate signals after binding to the VPAC2 receptor, which is expressed by immature pancreatic epithelial cells between embryonic days 12 and 16. Finally, in vitro, VIP exposure increased the survival and proliferation of immature pancreatic cells, leading to an increase in the number of endocrine cells that will develop.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502497     DOI: 10.2337/diabetes.52.1.85

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  G protein-coupled receptor signaling and sphingosine-1-phosphate play a phylogenetically conserved role in endocrine pancreas morphogenesis.

Authors:  Ioannis Serafimidis; Scott Heximer; Dimitris Beis; Anthony Gavalas
Journal:  Mol Cell Biol       Date:  2011-09-12       Impact factor: 4.272

2.  Efficient restricted gene expression in beta cells by lentivirus-mediated gene transfer into pancreatic stem/progenitor cells.

Authors:  M Castaing; A Guerci; J Mallet; P Czernichow; P Ravassard; R Scharfmann
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

3.  Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto-Kakizaki rat model of type 2 diabetes.

Authors:  S Calderari; M-N Gangnerau; M Thibault; M-J Meile; N Kassis; C Alvarez; B Portha; P Serradas
Journal:  Diabetologia       Date:  2007-05-03       Impact factor: 10.122

4.  Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance.

Authors:  Latif Rachdi; Dulanjalee Kariyawasam; Virginie Aïello; Yann Herault; Nathalie Janel; Jean-Maurice Delabar; Michel Polak; Raphaël Scharfmann
Journal:  Cell Cycle       Date:  2014-05-28       Impact factor: 4.534

5.  Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.

Authors:  Latif Rachdi; Dulanjalee Kariyawasam; Fanny Guez; Virginie Aïello; Maria L Arbonés; Nathalie Janel; Jean-Maurice Delabar; Michel Polak; Raphaël Scharfmann
Journal:  Diabetologia       Date:  2014-01-30       Impact factor: 10.122

6.  L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway.

Authors:  Latif Rachdi; Virginie Aïello; Bertrand Duvillié; Raphaël Scharfmann
Journal:  Diabetes       Date:  2011-12-30       Impact factor: 9.461

7.  Inhibition of central de novo ceramide synthesis restores insulin signaling in hypothalamus and enhances β-cell function of obese Zucker rats.

Authors:  Mélanie Campana; Lara Bellini; Claude Rouch; Latif Rachdi; Nicolas Coant; Noémie Butin; Cécile L Bandet; Erwann Philippe; Kelly Meneyrol; Nadim Kassis; Julien Dairou; Eric Hajduch; Benoit Colsch; Christophe Magnan; Hervé Le Stunff
Journal:  Mol Metab       Date:  2017-11-07       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.